YM BioSciences (YMI) surges 21.9% AH after reporting positive results for the Phase I/II study...
YM BioSciences (YMI) surges 21.9% AH after reporting positive results for the Phase I/II study of its CYT387 drug for treating myleofibrosis, both with regards to efficacy and safety. The company hopes to start "pivotal trials" for the drug in mid-2012.
From other sites
at 4-traders.com (Mar 24, 2015)
at MarketRealist.com (Mar 24, 2015)
at Nasdaq.com (Mar 17, 2015)
at Zacks.com (Mar 6, 2015)
at Benzinga.com (Feb 27, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs